Gilead Sciences Inc.

61.60+0.5100+0.83%Vol 4.84M1Y Perf -11.18%
Aug 8th, 2022 16:00 DELAYED
BID61.36 ASK61.81
Open61.00 Previous Close61.09
Pre-Market- After-Market61.62
 - -  0.02 0.03%
Target Price
72.71 
Analyst Rating
Moderate Buy 2.35
Potential %
18.04 
Finscreener Ranking
★★+     46.85
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★+     48.51
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★     58.08
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
★★★     45.58
Price Range Ratio 52W %
26.16 
Earnings Rating
Neutral
Market Cap77.27B 
Earnings Date
2nd Aug 2022
Alpha-0.00 Standard Deviation0.07
Beta0.38 

Today's Price Range

60.8161.71

52W Range

57.1774.12

5 Year PE Ratio Range

6.40823.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.46%
1 Month
-1.97%
3 Months
-0.13%
6 Months
-2.81%
1 Year
-11.18%
3 Years
-5.58%
5 Years
-16.64%
10 Years
118.16%

TickerPriceChg.Chg.%
GILD61.600.51000.83
AAPL164.87-0.4800-0.29
GOOG118.14-0.0800-0.07
MSFT280.32-2.5900-0.92
XOM88.950.50000.57
WFC43.19-0.5700-1.30
JNJ170.20-0.9100-0.53
FB196.640.99000.51
GE75.180.82001.10
JPM114.35-1.4100-1.22
 
ProfitabilityValueIndustryS&P 500US Markets
75.70
24.90
32.60
29.00
14.15
RevenueValueIndustryS&P 500US Markets
21.26B
16.95
7.01
-0.35
DividendsValueIndustryS&P 500US Markets
4.79
2.92
6.04
7.97
Payout ratio67.00
Earnings HistoryEstimateReportedSurprise %
Q02 20221.511.584.64
Q01 20221.772.1219.77
Q04 20211.530.69-54.90
Q03 20211.722.6554.07
Q02 20211.761.876.25
Q01 20212.062.080.97
Q04 20202.152.191.86
Q03 20201.832.1115.30
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.51-3.21Negative
9/2022 QR1.53-6.13Negative
12/2022 FY6.590.76Positive
12/2023 FY6.29-1.41Negative
Next Report Date-
Estimated EPS Next Report1.51
Estimates Count11
EPS Growth Next 5 Years %15.00
Volume Overview
Volume4.84M
Shares Outstanding1.25M
Shares Float1.26B
Trades Count50.93K
Dollar Volume297.23M
Avg. Volume6.51M
Avg. Weekly Volume6.76M
Avg. Monthly Volume5.93M
Avg. Quarterly Volume6.84M

Gilead Sciences Inc. (NASDAQ: GILD) stock closed at 61.6 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 4.84M shares and market capitalization of 77.27B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11800 people. Gilead Sciences Inc. CEO is Daniel O'Day.

The one-year performance of Gilead Sciences Inc. stock is -11.18%, while year-to-date (YTD) performance is -15.16%. GILD stock has a five-year performance of -16.64%. Its 52-week range is between 57.165 and 74.12, which gives GILD stock a 52-week price range ratio of 26.16%

Gilead Sciences Inc. currently has a PE ratio of 17.50, a price-to-book (PB) ratio of 3.94, a price-to-sale (PS) ratio of 3.59, a price to cashflow ratio of 7.40, a PEG ratio of 2.32, a ROA of 7.12%, a ROC of 11.06% and a ROE of 23.87%. The company’s profit margin is 14.15%, its EBITDA margin is 32.60%, and its revenue ttm is $21.26 Billion , which makes it $16.95 revenue per share.

Of the last four earnings reports from Gilead Sciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.51 for the next earnings report. Gilead Sciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Gilead Sciences Inc. is Moderate Buy (2.35), with a target price of $72.71, which is +18.04% compared to the current price. The earnings rating for Gilead Sciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gilead Sciences Inc. has a dividend yield of 4.79% with a dividend per share of $2.92 and a payout ratio of 67.00%.

Gilead Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.58, ATR14 : 1.39, CCI20 : -9.54, Chaikin Money Flow : -0.08, MACD : -0.23, Money Flow Index : 30.12, ROC : -0.75, RSI : 45.03, STOCH (14,3) : 41.55, STOCH RSI : 0.68, UO : 46.02, Williams %R : -58.45), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gilead Sciences Inc. in the last 12-months were: Andrew D. Dickinson (Option Excercise at a value of $0), Andrew Dickinson (Option Excercise at a value of $0), Anthony Welters (Option Excercise at a value of $0), Brett A. Pletcher (Option Excercise at a value of $0), Brett A. Pletcher (Sold 19 386 shares of value $1 283 364 ), Daniel O'Day (Option Excercise at a value of $0), Diane E. Wilfong (Option Excercise at a value of $926 536), Diane E. Wilfong (Sold 13 610 shares of value $986 725 ), Harish Manwani (Option Excercise at a value of $0), Jacqueline K. Barton (Option Excercise at a value of $0), Javier J. Rodriguez (Option Excercise at a value of $0), Jeffrey A. Bluestone (Option Excercise at a value of $0), Jeffrey Bluestone (Option Excercise at a value of $0), Johanna Mercier (Option Excercise at a value of $0), Kevin E. Lofton (Option Excercise at a value of $418 251), Merdad Parsey (Option Excercise at a value of $0), Merdad V. Parsey (Option Excercise at a value of $0), Sandra J. Horning (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (29.41 %)
5 (31.25 %)
5 (33.33 %)
Moderate Buy
1 (5.88 %)
1 (6.25 %)
1 (6.67 %)
Hold
11 (64.71 %)
10 (62.50 %)
9 (60.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.35
Moderate Buy
2.31
Moderate Buy
2.27

Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

CEO: Daniel O'Day

Telephone: +1 650 574-3000

Address: 333 Lakeside Drive, Foster City 94404, CA, US

Number of employees: 11 800

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

TipRanks News for GILD

Tue, 07 Jun 2022 13:05 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and PDS Biotechnology (PDSB)

- TipRanks. All rights reserved.

Fri, 13 May 2022 04:06 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), TRACON Pharmaceuticals (TCON) and Cogent Biosciences (COGT)

- TipRanks. All rights reserved.

Thu, 12 May 2022 16:39 GMT Gilead Sciences (GILD) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Tue, 03 May 2022 15:15 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Kymera Therapeutics (KYMR)

- TipRanks. All rights reserved.

Sat, 30 Apr 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Stryker (SYK)

- TipRanks. All rights reserved.

Fri, 29 Apr 2022 10:35 GMT Gilead Sciences (GILD) Receives a Hold from Needham

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 15:55 GMT Can Gilead Stock Gain Traction Following FDA Lifting Partial Hold

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 13:04 GMT Gilead Sciences (GILD) Receives a Buy from RBC Capital

- TipRanks. All rights reserved.

Fri, 08 Apr 2022 01:51 GMT Gilead Sciences (GILD) Gets a Buy Rating from RBC Capital

- TipRanks. All rights reserved.

Fri, 01 Apr 2022 02:36 GMT Gilead Sciences (GILD) Gets a Hold Rating from Robert W. Baird

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 07:55 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Catalent (CTLT)

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 16:36 GMT Gilead Sciences (GILD) Receives a Hold from Morgan Stanley

- TipRanks. All rights reserved.

Fri, 14 Jan 2022 13:06 GMT Gilead Sciences (GILD) Receives a Buy from Jefferies

- TipRanks. All rights reserved.

Mon, 10 Jan 2022 19:30 GMT Gilead Sciences: Attractive Dividend Yield and Improving Financials

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 01:47 GMT RBC Capital Believes Gilead Sciences (GILD) Still Has Room to Grow

- TipRanks. All rights reserved.

News

Stocktwits